[go: up one dir, main page]

DE60330150D1 - Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren - Google Patents

Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren

Info

Publication number
DE60330150D1
DE60330150D1 DE60330150T DE60330150T DE60330150D1 DE 60330150 D1 DE60330150 D1 DE 60330150D1 DE 60330150 T DE60330150 T DE 60330150T DE 60330150 T DE60330150 T DE 60330150T DE 60330150 D1 DE60330150 D1 DE 60330150D1
Authority
DE
Germany
Prior art keywords
aminopurins
inhibitoren
trifluormethyl
phosphodiesterase
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330150T
Other languages
German (de)
Inventor
Ruiping Liu
Allen T Hopper
Ashok Tehim
Hans-Jurgen E Hess
Yajing Rong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Memory Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceuticals Corp filed Critical Memory Pharmaceuticals Corp
Application granted granted Critical
Publication of DE60330150D1 publication Critical patent/DE60330150D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/14—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with two methyl radicals in positions 1 and 3 and two methyl radicals in positions 7, 8, or 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
DE60330150T 2002-08-08 2003-08-08 Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren Expired - Lifetime DE60330150D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40176502P 2002-08-08 2002-08-08
PCT/US2003/024914 WO2004014913A2 (en) 2002-08-08 2003-08-08 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors

Publications (1)

Publication Number Publication Date
DE60330150D1 true DE60330150D1 (en) 2009-12-31

Family

ID=31715731

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330150T Expired - Lifetime DE60330150D1 (en) 2002-08-08 2003-08-08 Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren

Country Status (9)

Country Link
US (3) US7332486B2 (en)
EP (1) EP1529049B1 (en)
JP (1) JP2005538134A (en)
CN (1) CN1688580A (en)
AT (1) ATE449099T1 (en)
AU (1) AU2003264017B2 (en)
CA (1) CA2494028A1 (en)
DE (1) DE60330150D1 (en)
WO (1) WO2004014913A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933236B2 (en) * 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
EP1383767A1 (en) * 2001-02-08 2004-01-28 Memory Pharmaceutical Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
US7335654B2 (en) * 2002-08-08 2008-02-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
CN1688580A (en) * 2002-08-08 2005-10-26 记忆药物公司 2-Trifluoromethyl-6-aminopurine derivatives as phosphodiesterase 4 inhibitors
US7138401B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
CA2602257A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
WO2006123639A1 (en) * 2005-05-18 2006-11-23 Asahi Kasei Pharma Corporation Pyrimidine derivative
EP1989188B1 (en) 2006-02-28 2015-07-22 Dart Neuroscience (Cayman) Ltd Therapeutic piperazines as pde4 inhibitors
FR2898057B1 (en) 2006-03-06 2008-07-04 Centre Nat Rech Scient USE OF ADENINE-DERIVED COMPOUNDS FOR THE TREATMENT OF LUPUS
CL2007002994A1 (en) * 2006-10-19 2008-02-08 Wyeth Corp HETEROCICLIC DERIVATIVE COMPOUNDS CONTAINING SULFAMOIL, INHIBITORS OF HSP90; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER, SUCH AS CANCER OF BREAST, COLON AND PROSTATE, BETWEEN OTHERS.
CN104945311A (en) 2009-01-19 2015-09-30 Abbvie公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX2011007681A (en) 2009-01-19 2011-08-08 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases.
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
JP6014154B2 (en) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Benzenesulfonamide compounds and their use as therapeutic agents
WO2013064984A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
BR112015000187A2 (en) 2012-07-06 2017-06-27 Genentech Inc benzamides substituted with n and methods of use thereof
KR20150131233A (en) 2013-03-14 2015-11-24 제넨테크, 인크. Substituted triazolopyridines and methods of use thereof
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
CR20160296A (en) 2013-11-27 2016-09-20 Genentech Inc BENZAMIDS REPLACED AND METHODS TO USE THEM
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
KR102412146B1 (en) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 Sodium channel blockers
EP3297989A1 (en) 2015-05-22 2018-03-28 Genentech, Inc. Substituted benzamides and methods of use thereof
CN108137477A (en) 2015-08-27 2018-06-08 基因泰克公司 Therapeutic compounds and its application method
CN108290881B (en) 2015-09-28 2021-12-07 健泰科生物技术公司 Therapeutic compounds and methods of use thereof
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
CN120753591A (en) 2016-02-09 2025-10-10 制定实验室公司 Transponder and sensor for implantable medical device and method of use thereof
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
MX388175B (en) 2016-10-17 2025-03-19 Genentech Inc THERAPEUTIC COMPOUNDS AND METHODS OF USING THEM
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN108395432A (en) * 2018-01-15 2018-08-14 吴江信凯医药科技有限公司 A kind of preparation method of 2- trifluoromethyls-adenine
CN112041313A (en) 2018-02-26 2020-12-04 基因泰克公司 Pyridine-sulfonamide compounds and their use against pain and related conditions
JP2021519788A (en) 2018-03-30 2021-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Condensation ring hydropyrido compound as a sodium channel inhibitor
TW202003490A (en) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 Therapeutic compounds and methods of use thereof
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919192A (en) * 1972-05-22 1975-11-11 Icn Pharmaceuticals 5-Amino-4-substituted imidazole nucleotides
US3917583A (en) * 1972-08-04 1975-11-04 Icn Pharmaceuticals 2-Substituted cyclic AMP derivatives
AR205247A1 (en) 1973-02-07 1976-04-21 Icn Pharmaceuticals PROCEDURE FOR PREPARING 2-SUBSTITUTED AMP DERIVATIVES
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5013829A (en) * 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
CA2114114C (en) 1992-06-15 2005-05-03 Nigel Robert Arnold Beeley Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
DE4230755A1 (en) 1992-09-14 1994-03-17 Schering Ag Phosphodiesterase IV inhibitors for kidney and ureter disease treatment - with eg (4-(3-(cyclopentyl oxy) 4-methoxyphenyl-2-pyrrolidinone) being specific for kidney and ureter tissue relaxation
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (en) 1992-12-23 1995-11-21 Celltech Ltd
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
DE19702785A1 (en) 1997-01-27 1998-07-30 Bayer Ag New cyclic urea derivatives
CA2295106C (en) 1997-06-24 2007-03-13 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
CN1130363C (en) 1997-11-12 2003-12-10 三菱化学株式会社 Purine derivatives and medicaments containing them as active ingredients
DE19882893T1 (en) * 1997-12-12 2001-02-22 Euro Celtique Sa Preparation of 3-substituted adenines
JP3542482B2 (en) 1997-12-25 2004-07-14 日研化学株式会社 3-anilino-2-cycloalkenone derivatives
US6319928B1 (en) * 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DE19935209A1 (en) 1999-07-27 2001-02-08 Truss Michael C Treatment of urinary incontinence and related disorders, by increasing intracellular cyclic adenosine monophosphate concentration, e.g. using adenyl cyclase stimulant such as forskolin
GB0011802D0 (en) 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
EP1383767A1 (en) * 2001-02-08 2004-01-28 Memory Pharmaceutical Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
CN1688580A (en) * 2002-08-08 2005-10-26 记忆药物公司 2-Trifluoromethyl-6-aminopurine derivatives as phosphodiesterase 4 inhibitors
US7335654B2 (en) * 2002-08-08 2008-02-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors

Also Published As

Publication number Publication date
AU2003264017A1 (en) 2004-02-25
WO2004014913A2 (en) 2004-02-19
CN1688580A (en) 2005-10-26
ATE449099T1 (en) 2009-12-15
EP1529049B1 (en) 2009-11-18
EP1529049A2 (en) 2005-05-11
US20070093510A1 (en) 2007-04-26
CA2494028A1 (en) 2004-02-19
AU2003264017B2 (en) 2010-05-27
WO2004014913A3 (en) 2004-07-29
US20080139583A1 (en) 2008-06-12
US20100004236A1 (en) 2010-01-07
US7332486B2 (en) 2008-02-19
JP2005538134A (en) 2005-12-15

Similar Documents

Publication Publication Date Title
DE60330150D1 (en) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
NO20062950L (en) 5,7-diaminopyrazolo-43-Dlpyrimidines with PDE-5 inhibitory activity
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
DE60311662D1 (en) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
SG169900A1 (en) 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
GB0127903D0 (en) Improvements relating to organic compounds
YU57603A (en) Phosphodiesterase 4 inhibitors
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
MXPA04004347A (en) Novel difunctional photoinitiators.
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
DE60112974D1 (en) Carbolinderivate
NO20054404L (en) 5,7-Diaminopyrazolo [4,3-D] Pyrimidines Useful in the Treatment of Hypertension
GEP20074198B (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
BG106585A (en) Kinase inhibitors as therapeutic agents
BR0210030A (en) Phenylpyridinecarbonylpiperazine derivative
DE60216233D1 (en) Carbolinderivate
EA200301100A1 (en) NEW PHTHALASINOSES
MXPA03009750A (en) Chemical compounds.
AU7824900A (en) Compounds and methods for inhibiting mrp1
IL166164A0 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
MXPA03003942A (en) Bis-heterocyclic compounds with antitumour and chemosensitising activity.
DE60041001D1 (en) SUBSTITUTED HOMOPIPERIDYLBENZIMIDAZOLANALOGA AS FUNDUSRELAXANTIA
BRPI0416678A (en) pyrazolpyrimidines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition